An open label, noncomparative clinical trial of intrathecal iopamidol in children was performed. Sixty-one subjects between the ages of 24 days and 17 years were studied. Opacification of the subarachnoid space was adequate in all cases. Mild adverse reactions were detected in 10% of the participants. Seizures, EEG alterations or other severe reactions did not occur. The findings confirm the efficacy and safety of iopamidol as an intrathecal contrast medium in pediatrics.